Friday, 18 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 19, 2026

Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

View original at globenewswire.com
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Initial results from STRO-004 Phase 1 study expected in mid-2026

    60% confidence

  • Exploratory biomarker analyses suggest potential for STRO-004 combination studies addressing specific indications in either early or late lines of treatment

    60% confidence

  • STRO-004's favorable tolerability and pharmacokinetic profile are expected to enable increased drug exposure and payload delivery, supporting superior depth and durability of response in the clinic

    60% confidence

  • STRO-004 preclinical data underscore the potential of next-generation ADCs to drive meaningful activity across multiple solid tumors

    60% confidence

  • Preclinical data strengthen confidence in STRO-004's potential across indications and underscore platform versatility to generate differentiated ADCs across many targets and payloads

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Industry Reckoning: Safety Warnings Collide With Slowdown-Driven Market Jitters
A wave of high-profile safety concerns — Dario Amodei's call for a global slowdown in frontier AI development, Microsoft's humanist AI code of conduct, and researcher departures from Anthropic and Google citing safety risks — is converging with investor unease, as seen in GE Vernova's 8.6% stock drop on the slowdown call and Palantir's 6% decline. The narrative reflects growing tension between rapid AI commercialization and mounting governance, safety, and market-sustainability concerns.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,297 source documents archived
Query this data → isubstrate.com
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 — Source | Via News | ViaNews EU